Curidium is focused on identifying targeted medicines and companion diagnostics to treat patients more effectively. The Company aims to more accurately define patient subgroups with different underlying disease mechanisms and to develop targeted drug therapies for these patient subgroups. More…
| “No drug is all bad or all good – it’s about who's going to have a positive response to a drug and who will have a suboptimal response. Personalized medicine, in my view, is the key. […] We need to have markers of positive response.” |
| Deputy Commissioner Janet Woodcock, M.D. of the Office of the Chief Medical Officer of the U.S. Food and Drug Administration (FDA). |
Many chronic human diseases are heterogeneous, which means that the patient population consists of different subgroups /subclasses potentially as a result of differing underlying disease mechanisms. By analyzing the genetic or molecular profile of a patient, doctors may someday have a more rational approach to prescribing therapy, patients may respond better and the costs of healthcare may be reduced. More…
